Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Precirix | 2022 | Series B | $88.2M | Brussels |
| Freeline | 2022 | Post Ipo Equity | $26.1M | Stevenage |
| Rondo Therapeutics | 2022 | Series A | $67.0M | Hayward |
| 21st.BIO | 2021 | Series Unknown | $97.1M | Virum |
| NorthSea Therapeutics | 2021 | Series C | $80.0M | Naarden |
| BIOMILQ | 2021 | Series A | $21.0M | Durham |
| Tarveda Therapeutics | 2021 | Series Unknown | $6.0M | Watertown |
| Aristea Therapeutics | 2021 | Series B | $63.0M | San Diego |
| NeRRe Therapeutics | 2021 | Series B | $27.6M | Stevenage |
| Bolt Biotherapeutics | 2021 | Post Ipo Equity | $15.0M | Redwood City |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 126 | Precirix | Series B | $88.2M | Brussels, Belgium |
| 127 | Freeline | Post Ipo Equity | $26.1M | Stevenage, United Kingdom |
| 128 | Rondo Therapeutics | Series A | $67.0M | Hayward, United States |
| 129 | 21st.BIO | Series Unknown | $97.1M | Virum, Denmark |
| 130 | NorthSea Therapeutics | Series C | $80.0M | Naarden, The Netherlands |
| 131 | BIOMILQ | Series A | $21.0M | Durham, United States |
| 132 | Tarveda Therapeutics | Series Unknown | $6.0M | Watertown, United States |
| 133 | Aristea Therapeutics | Series B | $63.0M | San Diego, United States |
| 134 | NeRRe Therapeutics | Series B | $27.6M | Stevenage, United Kingdom |
| 135 | Bolt Biotherapeutics | Post Ipo Equity | $15.0M | Redwood City, United States |
Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.
Freeline is a biotechnology company that develops transformative gene therapies for systemic debilitating diseases.
Rondo Therapeutics creates novel bispecific antibodies that activate the immune system to fight cancer.
21st Bio has the potential to replace and improve a wide range of meals and materials with appealing sustainable bio-based alternatives.
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.
Unlocking human potential with breakthrough mammary biotechnology.
Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.
Aristea Therapeutics is a developer of novel therapies created for autoimmune diseases.
NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.
Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy.
Hummingbird Bioscience focuses on the discovery and early development of oncology drugs.
Entasis Therapeutics is developing a portfolio of innovative cures.
BioPhero is a pioneer in providing low-cost bio-based pheromones for pest management.
ZELP aims to significantly reduce the environmental impact of the livestock industry.
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Stargazer Pharmaceuticals offers the therapy of standards disorder and manufacturer of pharmaceuticals products.
Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions.
ReViral is a biotechnology company that develops and offers antiviral therapies for patients.
NBE-Therapeutics is a biotech company that develops oncology treatments for cancer patients.
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Forendo Pharma is a developer of novel drugs intended for the treatment of urological and other endocrinological diseases.
AFYX Therapeutics is a clinical stage biopharmaceutical company
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Outpost Medicine is a biopharmaceutical company
Novo Holdings has invested in 154 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Novo Holdings's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 18 different industry categories.
Among tracked funding rounds, Hummingbird Bioscience received $125.0M in a Series C round. Novo Holdings's total known invested capital is $8.5B.
Novo Holdings's average investment size is $69.9M across its portfolio of 154 companies.
Recent Novo Holdings portfolio additions include Precirix, Freeline, Rondo Therapeutics, 21st.BIO, NorthSea Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors